• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Around $2M Bet On This Industrial Stock? Check Out These 3 Stocks Insiders Are Buying

    4/25/24 6:57:41 AM ET
    $HROW
    $NTIC
    $RXO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Industrial Specialties
    Industrials
    Get the next $HROW alert in real time by email

    Although U.S. stocks closed mixed on Wednesday, there were a few notable insider trades.

    When insiders purchase shares, it indicates their confidence in the company’s prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision.

    Below is a look at a few recent notable insider purchases. For more, check out Benzinga’s insider transactions platform.

    Northern Technologies International

    • The Trade: Northern Technologies International Corporation (NASDAQ:NTIC) Director Sarah E. Kemp acquired a total of 1,275 shares at  an average price of $15.70. To acquire these shares, it cost around $20,018.
    • What's Happening: On April 11, Northern Technologies International reported better-than-expected second-quarter adjusted EPS results.
    • What Northern Technologies International Does: Northern Technologies International Corp, or NTIC is a United States-based firm that develops and markets environmentally beneficial products and services world-wide either directly or through a network of joint ventures, distributors, and agents.

    Harrow

    • The Trade: Harrow, Inc. (NASDAQ:HROW) 10% owner Opaleye Management Inc. acquired a total of 20,000 shares at an average price of $10.23. To acquire these shares, it cost around $204,640.
    • What's Happening: On April 11, Craig-Hallum initiated coverage on Harrow with a Buy rating and announced a price target of $24.
    • What Harrow Does: Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market.

    Don’t forget to check out our premarket coverage here

    RXO

    • The Trade: RXO, Inc. (NYSE:RXO) 10% owner Farhad Nanji bought a total of 100,000 shares at an average price of $19.82. To acquire these shares, it cost around $1.98 million.
    • What's Happening: RXO said it will issue its first-quarter financial results before the opening bell on May 2, 2024.
    • What RXO Does: RXO Inc is a brokered transportation platform defined by cutting-edge technology and a nimble, asset-light business model, with the largest component being core truck brokerage business.

    Read More: Honeywell Likely To Report Higher Q1 Earnings; Here Are The Recent Forecast Changes From Wall Street’s Most Accurate Analysts

    Get the next $HROW alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HROW
    $NTIC
    $RXO

    CompanyDatePrice TargetRatingAnalyst
    RXO Inc.
    $RXO
    11/14/2025Underperform → Peer Perform
    Wolfe Research
    RXO Inc.
    $RXO
    11/11/2025Equal-Weight → Overweight
    Morgan Stanley
    Harrow Inc.
    $HROW
    7/11/2025$76.00Overweight
    Cantor Fitzgerald
    Harrow Inc.
    $HROW
    6/12/2025$62.00Buy
    BTIG Research
    Harrow Inc.
    $HROW
    6/10/2025Outperform
    William Blair
    RXO Inc.
    $RXO
    4/4/2025Outperform → Perform
    Oppenheimer
    RXO Inc.
    $RXO
    3/13/2025$24.00Buy
    Truist
    RXO Inc.
    $RXO
    3/7/2025$19.00Hold
    Deutsche Bank
    More analyst ratings

    $HROW
    $NTIC
    $RXO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Wilkerson Andrew M.

    4 - RXO, Inc. (0001929561) (Issuer)

    3/24/26 4:36:33 PM ET
    $RXO
    Transportation Services
    Consumer Discretionary

    SEC Form 4 filed by Kerr Jason S.

    4 - RXO, Inc. (0001929561) (Issuer)

    3/24/26 4:34:25 PM ET
    $RXO
    Transportation Services
    Consumer Discretionary

    SEC Form 4 filed by Harris James E

    4 - RXO, Inc. (0001929561) (Issuer)

    3/24/26 4:33:14 PM ET
    $RXO
    Transportation Services
    Consumer Discretionary

    $HROW
    $NTIC
    $RXO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    RXO Schedules First-Quarter 2026 Earnings and Investor Conference Call for May 7, 2026

    RXO (NYSE:RXO) will issue its first-quarter financial results before the opening of the New York Stock Exchange on Thursday, May 7, 2026. The company's results will be made available on www.rxo.com. The company will also hold a conference call at 8 a.m. EDT. Conference Call Access Information Live webcast online at: http://investors.rxo.com Call toll-free from U.S./Canada: +1 800-715-9871 International callers: +1 646-307-1963 Conference ID: 8661113 A replay of the conference call will be available through May 14, 2026, by calling toll-free (from U.S./Canada) +1 800-770-2030; international callers dial +1 609-800-9909. Use the passcode 8661113#. Additionally, the call will be archived

    4/2/26 8:30:00 AM ET
    $RXO
    Transportation Services
    Consumer Discretionary

    RXO Announces Expansion of RXO Extra™ Carrier Rewards Program, Providing Truckers With More Benefits

    Revamped program now includes exclusive access to a premium freight brokerage experience RXO (NYSE:RXO) a leading provider of asset-light transportation solutions, today announced it has expanded its RXO Extra™ marketplace, where carriers can access programs to help their business run more profitably and manage cash flow more efficiently. The marketplace now includes a premium load-booking experience exclusively for carriers that participate in the RXO Extra programs. "Thousands of carriers already save money and improve their cash flow by participating in RXO Extra's factoring and fuel discount programs," said Tom Reid, Vice President at RXO. "Now, those carriers – and many more – will

    3/26/26 8:30:00 AM ET
    $RXO
    Transportation Services
    Consumer Discretionary

    Harrow Announces Pricing of $50.0 Million Offering of Senior Unsecured Notes Due 2030

    NASHVILLE, Tenn., March 24, 2026 (GLOBE NEWSWIRE) -- Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the pricing of its private offering (the "Offering") of $50.0 million aggregate principal amount of 8.625% senior unsecured notes due 2030 (the "2030 Notes"). The 2030 Notes will be guaranteed on a senior unsecured basis by the Company's existing and future wholly-owned domestic restricted subsidiaries and any of its other restricted subsidiaries that guarantees or co-issues any of its indebtedness or any indebtedness of any of its subsidiaries that guarantees the 2030 Notes, subject to certain exceptions. The Offering is

    3/24/26 4:57:00 PM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HROW
    $NTIC
    $RXO
    SEC Filings

    View All

    SEC Form DEF 14A filed by RXO Inc.

    DEF 14A - RXO, Inc. (0001929561) (Filer)

    3/30/26 5:29:57 PM ET
    $RXO
    Transportation Services
    Consumer Discretionary

    SEC Form DEFA14A filed by RXO Inc.

    DEFA14A - RXO, Inc. (0001929561) (Filer)

    3/30/26 5:29:16 PM ET
    $RXO
    Transportation Services
    Consumer Discretionary

    Harrow Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Other Events, Financial Statements and Exhibits

    8-K - HARROW, INC. (0001360214) (Filer)

    3/27/26 4:05:13 PM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HROW
    $NTIC
    $RXO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Mfn Partners, Lp bought $6,387,312 worth of shares (532,276 units at $12.00) (SEC Form 4)

    4 - RXO, Inc. (0001929561) (Issuer)

    2/17/26 4:21:23 PM ET
    $RXO
    Transportation Services
    Consumer Discretionary

    Director Cooper Troy A. bought $88,243 worth of shares (8,317 units at $10.61), increasing direct ownership by 3% to 275,416 units (SEC Form 4)

    4 - RXO, Inc. (0001929561) (Issuer)

    11/24/25 8:00:06 AM ET
    $RXO
    Transportation Services
    Consumer Discretionary

    Amendment: Director Kingshott Adrian bought $100,512 worth of shares (9,350 units at $10.75), increasing direct ownership by 11% to 91,137 units (SEC Form 4)

    4/A - RXO, Inc. (0001929561) (Issuer)

    11/19/25 4:15:39 PM ET
    $RXO
    Transportation Services
    Consumer Discretionary

    $HROW
    $NTIC
    $RXO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    RXO, Inc. upgraded by Wolfe Research

    Wolfe Research upgraded RXO, Inc. from Underperform to Peer Perform

    11/14/25 9:43:16 AM ET
    $RXO
    Transportation Services
    Consumer Discretionary

    RXO, Inc. upgraded by Morgan Stanley

    Morgan Stanley upgraded RXO, Inc. from Equal-Weight to Overweight

    11/11/25 2:40:54 PM ET
    $RXO
    Transportation Services
    Consumer Discretionary

    Cantor Fitzgerald initiated coverage on Harrow with a new price target

    Cantor Fitzgerald initiated coverage of Harrow with a rating of Overweight and set a new price target of $76.00

    7/11/25 8:12:59 AM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HROW
    $NTIC
    $RXO
    Leadership Updates

    Live Leadership Updates

    View All

    Harrow Appoints Mike Biega as Vice President of Investor Relations and Communications

    Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, today announced that Mike Biega has joined Harrow as Vice President of Investor Relations and Communications, succeeding Jamie Webb, Director of Communications and Investor Relations, who recently announced her retirement. Jamie will remain in her role into August to support a smooth and effective transition. "We are excited to welcome Mike to the Harrow Family. His wealth of experience in investor relations and strategic communications will be a tremendous asset as we pursue our objective of becoming the leading U.S. ophthalmic pharmaceutical company," said Mark L. Baum, Chief Executive Officer of Harrow. "I a

    6/18/25 7:00:00 AM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Harrow Appoints Amir H. Shojaei as Chief Scientific Officer

    Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, today announced that Amir H. Shojaei, PharmD, PhD, has joined Harrow as Chief Scientific Officer (CSO). With a remarkable career spanning 28 years in life sciences, Dr. Shojaei brings deep expertise in clinical development, regulatory affairs, and the commercialization of biopharmaceutical and biologic products, including groundbreaking work in anterior and posterior segment ophthalmic indications. Dr. Shojaei most recently served as CSO and Executive Vice President of Clinical Development at AsclepiX Therapeutics, where he spearheaded the development of innovative therapies for neovascular retinal disorders. P

    1/7/25 7:00:00 AM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RXO Names Troy Cooper to Board of Directors

    RXO (NYSE:RXO), a leading provider of asset-light transportation solutions, announced the appointment of Troy Cooper to its Board of Directors. Brad Jacobs, non-executive chairman of RXO said, "Troy's deep understanding of the truck brokerage industry, coupled with his impressive operational and financial expertise, will be tremendous assets to both the RXO board and the company." Cooper is a transportation industry veteran with more than 11 years of experience in supply chain operations, including brokerage. He joined XPO in September 2011 as the senior vice president of operations and launched the company's Charlotte, N.C., truck brokerage hub (now part of RXO) in 2012. Later, Cooper

    6/14/24 6:30:00 AM ET
    $RXO
    Transportation Services
    Consumer Discretionary

    $HROW
    $NTIC
    $RXO
    Financials

    Live finance-specific insights

    View All

    RXO Schedules First-Quarter 2026 Earnings and Investor Conference Call for May 7, 2026

    RXO (NYSE:RXO) will issue its first-quarter financial results before the opening of the New York Stock Exchange on Thursday, May 7, 2026. The company's results will be made available on www.rxo.com. The company will also hold a conference call at 8 a.m. EDT. Conference Call Access Information Live webcast online at: http://investors.rxo.com Call toll-free from U.S./Canada: +1 800-715-9871 International callers: +1 646-307-1963 Conference ID: 8661113 A replay of the conference call will be available through May 14, 2026, by calling toll-free (from U.S./Canada) +1 800-770-2030; international callers dial +1 609-800-9909. Use the passcode 8661113#. Additionally, the call will be archived

    4/2/26 8:30:00 AM ET
    $RXO
    Transportation Services
    Consumer Discretionary

    Harrow Announces Q4 and Full-Year 2025 Financial Results and 2026 Financial Guidance

    Fourth Quarter, Full-Year 2025 and Selected Highlights:  Record quarterly revenue of $89.1 million, a 33% increase over $66.8 million recorded in the prior-year periodFull-Year revenue of $272.3 million, a 36% increase over $199.6 million recorded in 2024GAAP net income of $6.6 million in Q4 2025, and net loss $5.1 million for 2025Adjusted EBITDA of $24.2 million in Q4 2025, and $61.9 million for 2025Generated $43.9 million of operating cash flow in 2025, versus $(22.2) million used in operations in 2024Cash and cash equivalents of $72.9 million as of December 31, 2025Full-year 2026 revenue guidance of $350 million to $365 million, including $133 million to $153 million in the first half of

    3/2/26 4:05:00 PM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Harrow To Report Fourth Quarter and Year-End 2025 Financial Results After Market Close on March 2, 2026

    NASHVILLE, Tenn., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it will report its financial results for the fourth quarter and year ended December 31, 2025, on Monday, March 2, 2026, after the market close. The Company will also post its fourth quarter Letter to Stockholders to the "Investors" section of its website, harrow.com. Harrow will host a conference call and live webcast at 8:00 a.m. Eastern Time on Tuesday, March 3, 2026, to discuss the results and provide a business update. Conference Call InformationParticipants can access the live webcast of Harrow's presentation on

    2/18/26 7:00:00 AM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HROW
    $NTIC
    $RXO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Harrow Inc.

    SC 13G/A - HARROW, INC. (0001360214) (Subject)

    12/5/24 7:08:52 PM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Northern Technologies International Corporation

    SC 13G/A - NORTHERN TECHNOLOGIES INTERNATIONAL CORP (0000875582) (Subject)

    11/14/24 9:00:19 AM ET
    $NTIC
    Industrial Specialties
    Industrials

    Amendment: SEC Form SC 13G/A filed by Northern Technologies International Corporation

    SC 13G/A - NORTHERN TECHNOLOGIES INTERNATIONAL CORP (0000875582) (Subject)

    11/12/24 4:54:35 PM ET
    $NTIC
    Industrial Specialties
    Industrials